alogliptin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
dipeptidyl aminopeptidase-IV inhibitors 4340 850649-61-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vipidia
  • alogliptin
  • alogliptin benzoate
  • nesina
a selective, orally bioavailable inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4) that slows the inactivation of the incretin hormones, thereby increasing their bloodstream concentrations and reducing fasting and postprandial glucose concentrations in a glucose-dependent manner in patients with type 2 diabetes mellitus
  • Molecular weight: 339.40
  • Formula: C18H21N5O2
  • CLOGP: 1.27
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 93.67
  • ALOGS: -2.77
  • ROTB: 3
  • Status: ONP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
25 mg O

ADMET properties:

PropertyValueReference
S (Water solubility) 18 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Bocci G, Oprea TI, Benet LZ
fu (Fraction unbound in plasma) 0.84 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.503 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 5.284 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.081 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.820 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 81.150 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 75.380 % High 1
herg hERG pIC50 4.488 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.138 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.126 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 82.910 % High 1
kinase-safety-class ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP3K21,MAP3K7,MAPK10,MAPK7,MET,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PRKDC,SIK2,SIK3,STK33,TEK,ZAP70 35
kinase-selectivity-class AXL,CAMK2D,CDK9,GRK2,IRAK1,MET,PRKDC,SIK2,TEK 9
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.451 High 1
mh-clint Mouse hepatocyte intrinsic clearance 5.861 High 1
mppb Mouse plasma protein binding (% unbound) 79.140 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 6.194 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 90.640 % High 1
rh-clint Rat hepatocyte intrinsic clearance 2.661 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 90.680 % High 1
rppb Rat plasma protein binding (% unbound) 82.850 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 970.510 uM High 1

Approvals:

DateAgencyCompanyOrphan
Jan. 25, 2013 FDA TAKEDA PHARMS USA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 110.29 26.17 29 2394 8997 90617027
Cerebral infarction 54.31 26.17 22 2401 26574 90599450
Pancreatic carcinoma 44.16 26.17 14 2409 8363 90617661
Erythema multiforme 38.95 26.17 14 2409 12232 90613792
Diabetic ketoacidosis 32.72 26.17 15 2408 24392 90601632
Pancreatitis acute 28.81 26.17 15 2408 32100 90593924
Interstitial lung disease 27.74 26.17 20 2403 76385 90549639
Euglycaemic diabetic ketoacidosis 27.13 26.17 9 2414 6192 90619832
Hypoglycaemic encephalopathy 26.55 26.17 5 2418 336 90625688

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 210.41 21.89 64 3281 11403 42606587
Pancreatitis 77.55 21.89 46 3299 43222 42574768
Cerebral infarction 71.64 21.89 39 3306 31130 42586860
Pancreatitis acute 50.67 21.89 32 3313 33532 42584458
Interstitial lung disease 48.90 21.89 44 3301 78418 42539572
Diabetic ketoacidosis 45.92 21.89 26 3319 22341 42595649
Tonsil cancer 41.84 21.89 11 3334 1150 42616840
Spondylolysis 41.23 21.89 7 3338 84 42617906
Lumbosacral radiculoplexus neuropathy 34.35 21.89 6 3339 86 42617904
Lactic acidosis 33.45 21.89 28 3317 45233 42572757
Gastric cancer 32.10 21.89 14 3331 6889 42611101
Application site haematoma 30.28 21.89 5 3340 50 42617940
Euglycaemic diabetic ketoacidosis 28.02 21.89 12 3333 5648 42612342
Angina pectoris 27.78 21.89 22 3323 32874 42585116
Appetite disorder 27.69 21.89 10 3335 3005 42614985
Hypoglycaemia 26.76 21.89 28 3317 59826 42558164
Drug-induced liver injury 24.86 21.89 22 3323 38251 42579739
Angioedema 24.81 21.89 23 3322 42454 42575536
Glycosylated haemoglobin increased 23.79 21.89 14 3331 12910 42605080
Hepatocellular carcinoma 23.78 21.89 12 3333 8182 42609808
Joint lock 22.27 21.89 7 3338 1378 42616612

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pemphigoid 325.42 21.13 93 5821 19614 110563771
Cerebral infarction 124.46 21.13 59 5855 51779 110531606
Pancreatitis acute 79.66 21.13 46 5868 60228 110523157
Interstitial lung disease 79.20 21.13 63 5851 139271 110444114
Diabetic ketoacidosis 77.50 21.13 40 5874 42018 110541367
Pancreatitis 77.30 21.13 53 5861 93480 110489905
Euglycaemic diabetic ketoacidosis 53.58 21.13 21 5893 11602 110571783
Lactic acidosis 52.78 21.13 42 5872 92769 110490616
Pancreatic carcinoma 48.57 21.13 21 5893 14851 110568534
Hepatocellular carcinoma 46.07 21.13 18 5896 9862 110573523
Hypoglycaemia 44.61 21.13 42 5872 116062 110467323
Gastric cancer 44.18 21.13 18 5896 10990 110572395
Tonsil cancer 39.72 21.13 10 5904 1296 110582089
Erythema multiforme 38.66 21.13 20 5894 21077 110562308
Spondylolysis 37.33 21.13 7 5907 226 110583159
Lumbosacral radiculoplexus neuropathy 34.91 21.13 6 5908 117 110583268
Drug eruption 32.03 21.13 25 5889 53634 110529751
Hepatic function abnormal 31.82 21.13 31 5883 89264 110494121
Body temperature decreased 30.65 21.13 21 5893 36914 110546471
Application site haematoma 30.14 21.13 5 5909 78 110583307
Renal impairment 29.56 21.13 43 5871 188402 110394983
Cardiac failure 28.25 21.13 42 5872 187584 110395801
Blood glucose increased 28.06 21.13 35 5879 132461 110450924
Diabetes mellitus inadequate control 27.27 21.13 18 5896 29757 110553628
Angina pectoris 26.76 21.13 24 5890 62271 110521114
Glycosylated haemoglobin increased 25.91 21.13 16 5898 23603 110559782
Drug-induced liver injury 25.87 21.13 32 5882 120035 110463350
Colon cancer 25.64 21.13 14 5900 16429 110566956
Acute kidney injury 25.31 21.13 83 5831 635347 109948038
Altered state of consciousness 24.36 21.13 22 5892 57604 110525781
Angioedema 24.09 21.13 28 5886 98472 110484913
Hyperkalaemia 22.77 21.13 32 5882 135764 110447621
Diabetic nephropathy 22.22 21.13 8 5906 3500 110579885
Joint lock 22.04 21.13 8 5906 3580 110579805
Platelet count decreased 21.90 21.13 42 5872 230401 110352984
Constipation 21.26 21.13 54 5860 357732 110225653

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BD09 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BD13 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Combinations of oral blood glucose lowering drugs
ATC A10BH04 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Dipeptidyl peptidase 4 (DPP-4) inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D006728 Hormones
MeSH PA D007004 Hypoglycemic Agents
MeSH PA D011480 Protease Inhibitors
MeSH PA D054795 Incretins
MeSH PA D054873 Dipeptidyl-Peptidase IV Inhibitors
FDA MoA N0000175912 Dipeptidyl Peptidase 4 Inhibitors
FDA EPC N0000175913 Dipeptidyl Peptidase 4 Inhibitor
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:68612 EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor

Related Drugs by ATC class:

A10BD Combinations of oral blood glucose lowering drugs 19 drugs
acarbosecanagliflozindapagliflozinempagliflozinertugliflozinevogliptingemigliptinglimepiridelinagliptinlobeglitazonemetforminphenformin show all 19 →
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 9 drugs
evogliptingemigliptinlinagliptinrosuvastatinsaxagliptinsimvastatinsitagliptinteneligliptinvildagliptin

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.4 Basic
pKa2 1.33 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 12.5MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 6.25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 DISCN TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 15MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 30MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 25MG BASE;EQ 45MG BASE OSENI TAKEDA PHARMS USA N022426 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL 7807689 June 27, 2028 METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 12.5MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL July 27, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
EQ 25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL July 27, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
EQ 6.25MG BASE NESINA TAKEDA PHARMS USA N022271 Jan. 25, 2013 RX TABLET ORAL July 27, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
EQ 12.5MG BASE;1GM KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL July 27, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST
EQ 12.5MG BASE;500MG KAZANO TAKEDA PHARMS USA N203414 Jan. 25, 2013 RX TABLET ORAL July 27, 2026 REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY SYR-322-309, CONDUCTED IN RESPONSE TO A PEDIATRIC WRITTEN REQUEST

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Dipeptidyl peptidase 4 Enzyme INHIBITOR IC50 9 CHEMBL CHEMBL
Dipeptidyl peptidase 4 Enzyme IC50 8.07 CHEMBL

External reference:

IDSource
4032098 VUID
N0000186570 NUI
D06553 KEGG_DRUG
4032097 VANDF
4032098 VANDF
C1958126 UMLSCUI
CHEBI:72323 CHEBI
T22 PDB_CHEM_ID
CHEMBL376359 ChEMBL_ID
CHEMBL227529 ChEMBL_ID
DB06203 DRUGBANK_ID
C520853 MESH_SUPPLEMENTAL_RECORD_UI
6319 IUPHAR_LIGAND_ID
8814 INN_ID
850649-62-6 SECONDARY_CAS_RN
JHC049LO86 UNII
11450633 PUBCHEM_CID
1368000 RXNORM
198438 MMSL
237036 MMSL
29087 MMSL
399893 MMSL
d07963 MMSL
014872 NDDF
014873 NDDF
702799001 SNOMEDCT_US
702800002 SNOMEDCT_US
703669009 SNOMEDCT_US
JHC049LO86 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 45802-087 TABLET, FILM COATED 6.25 mg ORAL NDA authorized generic 28 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 45802-103 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 28 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 45802-150 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 28 sections
alogliptin and metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 45802-169 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 29 sections
alogliptin and metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 45802-211 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 29 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-260 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 31 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-351 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 31 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-402 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 31 sections
Alogliptin and Pioglitazone HUMAN PRESCRIPTION DRUG LABEL 2 45802-499 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 31 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 50090-5574 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 27 sections
alogliptin and metformin hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 50090-5993 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 28 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 63629-4946 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 27 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-123 TABLET, FILM COATED 12.50 mg ORAL NDA 32 sections
Nesina HUMAN PRESCRIPTION DRUG LABEL 1 64764-125 TABLET, FILM COATED 12.50 mg ORAL NDA 31 sections
Nesina HUMAN PRESCRIPTION DRUG LABEL 1 64764-250 TABLET, FILM COATED 25 mg ORAL NDA 31 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-251 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-253 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
OSENI HUMAN PRESCRIPTION DRUG LABEL 2 64764-254 TABLET, FILM COATED 25 mg ORAL NDA 32 sections
KAZANO HUMAN PRESCRIPTION DRUG LABEL 2 64764-335 TABLET, FILM COATED 12.50 mg ORAL NDA 30 sections
KAZANO HUMAN PRESCRIPTION DRUG LABEL 2 64764-337 TABLET, FILM COATED 12.50 mg ORAL NDA 30 sections
Nesina HUMAN PRESCRIPTION DRUG LABEL 1 64764-625 TABLET, FILM COATED 6.25 mg ORAL NDA 31 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 71610-300 TABLET, FILM COATED 25 mg ORAL NDA authorized generic 28 sections
Alogliptin HUMAN PRESCRIPTION DRUG LABEL 1 71610-661 TABLET, FILM COATED 12.50 mg ORAL NDA authorized generic 28 sections